SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Market participants are fixated on rising geopolitical tensions following a 48-hour ultimatum regarding the Strait of Hormuz, sparking concerns over global energy supply and inflationary pressures. The community is actively debating the potential for a rapid military de-escalation versus the risk of a broader economic shock, while institutional hedging and extreme volatility have triggered widespread calls for caution.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing intense volatility and downward pressure as investors abandon the metal amid a strengthening dollar and surging bond yields. The community is sharply divided, with many debating whether this is a structural failure of gold's safe-haven narrative or a massive liquidity flush offering a generational buying opportunity.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging due to intense market focus on natural gas supply disruptions caused by the recent conflict in the Middle East, which has elevated the stock's status as a key play for European energy security. The community is actively discussing a potential short squeeze fueled by massive trading volume and extremely limited share availability for borrowing, with many traders drawing parallels to previous parabolic runs in the energy sector.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Market participants are reacting to heightened geopolitical tensions in the Middle East, specifically the escalating rhetoric between the U.S. and Iran following a 48-hour ultimatum regarding the Strait of Hormuz. Community discussion is dominated by concerns over potential energy supply disruptions, fears of a broader conflict impacting global infrastructure, and speculation on how these macro events will influence the trajectory of tech-heavy indices.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently drawing intense investor focus as it navigates significant volatility, driven by a blend of technical selling, ongoing geopolitical tensions impacting energy markets, and skepticism regarding the ambitious 'Terafab' chip manufacturing initiative. The community is deeply divided, with bulls pointing to the company's long-term potential in AI and robotics, while bears are highlighting disappointing financial performance and legal scrutiny regarding past statements.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

Investors are actively debating the sustainability of the current AI-led market rally, with many using SQQQ as a strategic hedge against geopolitical instability in the Middle East and concerns over stretched equity valuations. Community sentiment is deeply divided between those betting on an imminent market pullback due to economic cooling and those wary of the structural decay risks inherent in holding inverse leveraged ETFs for the long term.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors react to news of a manufacturing flaw involving wiring issues on certain 737 MAX jets, which has temporarily slowed deliveries. While the company maintains that the repairs are minor and will not impact long-term production targets, the community remains divided between those viewing the pullback as a buying opportunity given the strong commercial backlog and those concerned about persistent quality control challenges.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

VanEck Gold Miners ETF (GDX) is facing intense volatility as the precious metals sector undergoes a sharp correction, fueled by a strengthening U.S. dollar, rising treasury yields, and a broader market reassessment of the gold-as-a-safe-haven narrative amid Middle Eastern tensions. While some investors are treating the pullback as an accumulation opportunity, the community is actively debating whether the recent steep drawdown represents a structural change or a temporary flush of overleveraged positions before a potential recovery.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors weigh strong China smartphone sales against broader market concerns over stagflation, geopolitical volatility in the Middle East, and the potential impact of interest rate uncertainty on tech valuations. While some in the community highlight the firm's resilient hardware ecosystem and AI-driven growth potential, many are actively debating the stock's recent underperformance and technical breakdown, with traders focused on critical support levels near the 200-day moving average.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as geopolitical volatility in the Middle East intensifies following a high-stakes 48-hour ultimatum by the U.S. regarding the Strait of Hormuz. The community is actively debating whether energy prices will continue to spike due to potential supply infrastructure disruptions or if the market has already reached a short-term peak as diplomatic chatter and military deployment news create deep uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat Ratings reports. One...

Promising Biotech Stocks To Keep An Eye On - March 21st

Danaher, Vertex Pharmaceuticals, Moderna, United Therapeutics, ImmunityBio, argenex, and Medpace are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

ImmunityBio (NASDAQ:IBRX) Stock Price Down 4%  - Should You Sell?

ImmunityBio (NASDAQ:IBRX) Trading Down 4% - Time to Sell...

ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the recipient of unusually large options trading on Friday. Investors acquired 51,571 call options on the stock. This is an increase of 50...

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA in BCG-Unresponsive NMIBC with CIS Papillary Tumors

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the Peoples Republic of China has granted...

<ul class="summary-bullets"><li>A record $5.7 trillion “triple witching” options expiry threatens to inject fresh swings into an already fragile market.</li><li>Markets remain on edge as escalating Middle East tensions fuel oil volatility.</li><li>SMCI stock tanks 20% in early pre-market trade on alleged Nvidia chip diversion to China.&nbsp;</li></ul>U.S. stock futures took a breather early Friday with investors parsing the latest developments in the Middle East. However, fresh Israeli strikes on Iran and risks around the Strait of Hormuz are keeping oil volatility in action.Traders will also be&nbsp; focusing on a historic options expiration. They are&nbsp; bracing for a staggering $5.7 trillion in notional options to expire today, which is reportedly the largest March expiry in Citigroup data going back to 1996.&nbsp; As of 4:00 a.m. ET on Friday, Dow futures rose 0.2%, S&amp;P futures gained 0.1%, the Nasdaq futures were flat with a positive bias, and Russell 2000 futures were up 0.3%.Caution prevails among the traders. Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, remained ‘extremely bearish, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has remained ‘bearish’ amid high trading volume.&nbsp;Trending Stocks To Watch Super Micro Computer (SMCI):&nbsp;The stock is on retail radar this morning after U.S. prosecutors charged three individuals, including a co-founder and a board member, in a scheme to smuggle Nvidia (NVDA) chips to China. Both companies have stressed on compliance in their statements.&nbsp;Nvidia (NVDA) &amp; Amazon (AMZN):&nbsp;Despite the SMCI scandal, Nvidia remains in focus following reports it will sell 1 million chips to Amazon by the end of 2027 as part of a massive cloud infrastructure deal. Amazon also boosted its logistics wing by acquiring the autonomous robotics startup Rivr.Meta (META): The company reportedly reversed its decision to shut down&nbsp;Horizon Worlds for Quest VR headsets, citing fan feedback.Tech stocks also remain in the spotlight on reports that the White House is expected to release a&nbsp;national AI regulatory framework in the coming days.&nbsp;Tesla (TSLA):&nbsp;The EV giant is back in focus as it doubles down on its solar and energy ambitions with a $2.9 billion China-linked expansion, while also nearing a potential rollout of its Full Self-Driving (FSD) software in Europe.FedEx (FDX): The stock is garnering retail attention following a Q3 earnings beat and a raised FY26 outlook. Analysts at Wells Fargo and JPMorgan raised price targets to $430–$432.&nbsp;Investors are shifting focus to&nbsp;rare earth stocks (MP, UAMY, USAR) following a landmark joint action plan between the U.S. and Japan. The two nations announced a $73 billion energy and minerals initiative, including the development of deep-sea rare earth muds near Minamitori Island.&nbsp;Azitra Inc. (AZTR):&nbsp;The stock is seeing strong pre-market action following the pricing of a $31.4 million private placement financing.ImmunityBio, Inc. (IBRX): Its cancer therapy Anktiva appeared on Macau’s latest drug list. Also, the founder has flagged early immune activation data from an Anktiva study.Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Firefly Aerospace (FLY), AppLovin Corp (APP), and Qualcom (QCOM).&nbsp;On earnings radar, watch out for quarterly reports from Milestone Scientific (MIST), XPeng (XPEV), and Zegna (ZGN) before the bell today.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Take A Breather Ahead Of Massive Options Expiry: Why SMCI, NVDA, TSLA, UAMY, IBRX Are Keeping Traders Engaged Today

Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ. 

Equity

Data from Stocktwits indicated that retail sentiment remains bearish on SPY and QQQ. 


<ul class="summary-bullets"><li>Executive chairman Patrick Soon-Shiong highlighted early immune activation data from an Anktiva study.</li><li>Anktiva was also added to Macau’s drug list and included in updated NCCN guidelines for papillary bladder cancer.</li><li>ImmunityBio has resubmitted its FDA application for label expansion, while advancing lung cancer trials and expanding global approvals.</li></ul>Shares of ImmunityBio, Inc. (IBRX) posted modest gains in premarket trading on Friday after executive chairman and founder Patrick Soon-Shiong flagged early immune data from an Anktiva study, adding to momentum from recent regulatory and global developments.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained over 5% this week, snapping a two-week losing streak that had erased nearly 15% of its value.<h2 class="st-heading-2">Early Anktiva Data Shows Immune Activation</h2>Soon-Shiong said in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2034892413802545271">post on X</a> that initial analysis from the first 20 subjects showed immune activation with Anktiva in combination with the company’s adenovirus-based cancer vaccine. The trial has enrolled 138 patients randomized to the combination or placebo. Data generated by the U.S. National Cancer Institute team showed confirmation of Anktiva’s immune-stimulating effect on absolute lymphocyte count.He added that baseline lymphocyte levels decline with age but appear to increase with Anktiva, citing research linking low levels to reduced lifespan. Soon-Shion also added that cancer vaccine trials are ongoing.<h2 class="st-heading-2">Anktiva Gains Macau Listing, NCCN Backing</h2>The update comes as Anktiva was added to Macau’s latest&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-snap-losing-streak-anktiva-macau-drug-list/cZ3XLBrRIhU">approved drug</a> list as a bladder cancer treatment. The inclusion places it alongside therapies from Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Gilead Sciences and Moderna.In the U.S., the National Comprehensive Cancer Network (NCCN) added Anktiva with BCG as an “other recommended” option for papillary bladder cancer that no longer responds to BCG, expanding its use beyond carcinoma in situ.<h2 class="st-heading-2">Anktiva Pipeline Expands With Strong Data</h2>ImmunityBio has resubmitted its application to expand Anktiva’s label to papillary bladder cancer after a prior refusal-to-file. In the Phase 2/3 Quilt 3.032 study, 58.2% of patients remained cancer-free at 12 months, while more than 80% avoided bladder removal surgery over three years, according to the company.The therapy is also being studied in lung cancer, with two pivotal trials underway, and has received authorizations in the U.K., Europe and Saudi Arabia.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX slid to ‘bearish’ from the ‘extremely bullish’ zone over the past three months amid over a 300% surge in message volumes over the same period.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_ba9f17d55e.webp" alt="ibrx ss.png" width="963" height="143"><figcaption>IBRX sentiment and message volume as of March 20 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/ActionCuresFear/message/648063131">said</a>, The market prices a bladder cancer drug. NCI just showed data proving it works on immune decline in people without cancer.”<stembedurl>https://stocktwits.com/ActionCuresFear/message/648063131</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Adi121/message/648063344">said</a>, “Anktiva is heading towards becoming universal cancer vaccine! Lynch syndrome is the proof of concept!”<stembedurl>https://stocktwits.com/Adi121/message/648063344</stembedurl>IBRX stock has more than tripled over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dr. Patrick Soon-Shiong arrives at Trump National Golf Club Bedminster in Bedminster Township, N.J. on Saturday, Nov. 19, 2016. (Photo by Jabin Botsford/The Washington Post via Getty Images)

IBRX Stock Rises Premarket As Founder Flags Early Anktiva Immune Data — Macau Nod Fuels Bull Case

 Early trial data showed immune activation in initial patients, with Anktiva boosting lymphocyte levels.

<ul class="summary-bullets"><li>The therapy also gained momentum in the U.S. after NCCN added it as a treatment option for papillary bladder cancer patients unresponsive to BCG.</li><li>ImmunityBio has resubmitted its FDA application to expand Anktiva’s use, backed by clinical data showing strong cancer-free and bladder preservation rates.</li><li>The company is advancing Anktiva globally, with lung cancer trials underway and recent approvals in markets including Saudi Arabia.</li></ul>Shares of ImmunityBio, Inc. (IBRX) are set to snap a two-week losing streak after its cancer therapy Anktiva appeared on Macau’s latest drug list, adding to fresh momentum from a U.S. guideline expansion.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained over 5% this week, snapping a two-week losing streak that had erased nearly 15% of its value.<h2 class="st-heading-2">Anktiva Added To Macau Approved List</h2>Anktiva, which is available under the generic name Nogapendekin alfa, is an immunotherapy that helps activate the body’s immune system to better fight cancer. It is approved in the U.S. for use with standard BCG treatment in patients with a type of bladder cancer that no longer responds to BCG, including those with or without certain tumor growths.The Macau filing, with data as of March, lists Anktiva as a bladder cancer treatment, identifying Nogapendekin alfa as its active ingredient and noting it is given as an injection for bladder cancer. The list also includes therapies approved by regulators such as the U.S. Food and Drug Administration (FDA), China’s National Medical Products Administration (NMPA), and the European Medicines Agency (EMA).Anktiva’s inclusion places it alongside a roster of globally approved therapies from major drugmakers, including Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Janssen, Gilead Sciences, and Moderna, positioning it among established treatments across oncology and specialty care.<h2 class="st-heading-2">NCCN Expansion Adds To Momentum</h2>The Macau development comes in the same week that Anktiva was added to updated U.S. treatment guidelines. The National Comprehensive Cancer Network (NCCN) added Anktiva, used with BCG, as an “other recommended” option for patients with papillary bladder cancer that no longer responds to BCG and has not spread into muscle tissue.Earlier versions of the guidelines had included the therapy only for carcinoma in situ. The update expands the potential patient population under clinical guidance, even as the indication is not yet formally approved by the FDA.<h2 class="st-heading-2">Anktiva Seeks Label Expansion</h2>ImmunityBio is seeking to expand Anktiva’s label to include papillary bladder cancer and has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-declines-immunitybio-resubmits-anktiva-application-to-fda/cZdVj9URIIL">resubmitted</a> its supplemental biologics license application to the FDA after previously receiving a refusal-to-file letter. The filing includes additional data requested by the agency, including updated efficacy results and long-term follow-up.Clinical data from the Phase 2/3 Quilt 3.032 study showed that 58.2% of patients remained cancer-free at 12 months, while more than 80% avoided bladder removal surgery over a three-year follow-up period, according to the company.<h2 class="st-heading-2">Global Push For Anktiva Grows</h2>Beyond bladder cancer, ImmunityBio is advancing Anktiva in lung cancer, with two pivotal trials underway in first-line and second-line non-small cell lung cancer. The company said multiple countries have expressed interest in the program as it explores broader regulatory pathways.The therapy has already received authorizations in the U.K., Europe and Saudi Arabia. In January, Saudi regulators granted approvals covering both bladder cancer and metastatic non-small cell lung cancer, including use in combination with checkpoint inhibitors.ImmunityBio said product shipments are ready to begin for a Saudi launch of Anktiva for bladder cancer, following regulatory approvals, and that it has partnered with regional distributors to expand access across the Middle East and North Africa.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX slid to ‘bearish’ from the ‘extremely bullish’ zone over the past three months amid over a 300% surge in message volumes over the same period.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_ba9f17d55e.webp" alt="ibrx ss.png" width="963" height="143"><figcaption>IBRX sentiment and message volume as of March 20 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/cyberInvest/message/648013012">said</a>, “Macau - China. I’d say that’s kinda global. And unstoppable.”<stembedurl>https://stocktwits.com/cyberInvest/message/648013012</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/cyberInvest/message/648034961">said</a>, “with NMPA - Macau - China approval apparent, FDA needs to get with it. This level of disfunction is a national embarrassment. China approves before US for a US company??? This is like a Saturday Night Live skit.”<stembedurl>https://stocktwits.com/cyberInvest/message/648034961</stembedurl>IBRX stock has more than tripled over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List 

IBRX Stock - Anktiva, an immunotherapy for bladder cancer, was listed in Macau’s March filing alongside globally approved drugs from major pharma players.

Anktiva, an immunotherapy for bladder cancer, was listed in Macau’s March filing alongside globally approved drugs from major pharma players.

ImmunityBio (NASDAQ:IBRX) Shares Up 3%  - Should You Buy?

ImmunityBio (NASDAQ:IBRX) Stock Price Up 3% - Here's Why...

ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.3% - Here's Why

ImmunityBio (NASDAQ:IBRX) Shares Up 4.3% - Should You Buy...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

With 132M shares short and 100% utilization, traders are betting on a massive, rapid breakout as trapped short sellers look for an exit.

Strategic partnership reports for local manufacturing in Riyadh signal significant international validation and revenue potential in the MENA region.

Investors are closely watching new federal cancer vaccine initiatives and potential federal funding that could drastically accelerate treatment adoption.

Recent regulatory approvals in Macau provide a critical beachhead for expansion into broader Asian markets and China.

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IBRX News

IBRXImmunityBio Inc